Donald Trump’s recent medical examination, hailed by his physician as evidence of ‘excellent health’, has been dismissed by leading British doctors as little more than a public relations stunt. The former president’s health summary, released last week, lacked the granular detail expected from a UK-based medical assessment. This is a market where information asymmetry creates inefficient outcomes.
When it comes to personal health of a potential head of state, opacity is a liability. A British medical transparency standard, as advocated by the Royal College of Physicians, demands full disclosure of raw data, not cherry-picked metrics. Trump’s report, notably bereft of cholesterol breakdown or cognitive test specifics, resembles a corporate earnings release that glosses over non-GAAP adjustments.
Investors, or in this case voters, deserve a clean, audited balance sheet. The comparison highlights a transatlantic divergence in healthcare governance: the UK’s National Health Service prides itself on standardised, accountable reporting, while the US system often indulges in ‘optics’ over substance. For a figure whose brand is built on deal-making and transparency, this feels like a missed opportunity to signal fitness for office.
Markets dislike uncertainty; a full clinical work-up would have been the equivalent of a solid dividend hike. Instead, we get a headline yield with no prospectus. The British approach reminds us that in medicine, as in finance, the devil is in the footnotes.
Until Trump releases his full medical dossier, the market for his candidacy will trade at a discount, reflecting the risk premium of the unknown.
